Effect of metformin and pioglitazon in treatment of fatty liver
Phase 3
- Conditions
- on alcoholic fatty liver disease.Fatty (change of) liver, not elsewhere classifiedK76.0
- Registration Number
- IRCT20150706023083N2
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 68
Inclusion Criteria
Age range 18_65 years old
Patients based on ultrasound evidence and testing of non-alcoholic fatty liver
Exclusion Criteria
People under the age of 18
Pregnant and lactating women
People with kidney failure 30> GFR
People with heart failure HF Class 3 and 4
People with liver cirrhosis
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum Spartate Aminotransferase Level. Timepoint: On arrival and after intervention. Method of measurement: Laboratory methods with Kits.;Grade sonography. Timepoint: On arrival and after intervention. Method of measurement: Ultrasound machine.;Serum levels of alanine amino transferase. Timepoint: On arrival and after intervention. Method of measurement: Laboratory methods with Kits.
- Secondary Outcome Measures
Name Time Method